Capital Deployment: $16.5 Billion in 2025Narrow moat

Thermo Fisher Scientific (TMO) — moat facet

Thermo Fisher spent $16.5 billion in 2025, most of it on acquisitions, and free cash flow covered less than half.

Thermo Fisher describes its priorities plainly: "our capital deployment strategy continues to prioritize strategic M&A complemented by a return of capital to our shareholders"1. In 2025 it deployed approximately $16.5 billion, $13 billion committed to acquisitions and $3.6 billion returned2.

Capital deployed, 2025 ($bn)13.0Acquisitions committed3.6Returned to shareholders6.3Free cash flowThermo Fisher Q4 2025 results release
Deployment was more than twice free cash flow.

The returns are mostly buybacks. The company bought back $3,000 million of stock in 2025 and paid $636 million of dividends3. In the first half of 2026 it bought back $4,000 million4, twice the $2,000 million of a year earlier, and it plans about $4 billion for the year5.

The dividend is small: $1.88 a share, a 0.28% yield6. Repurchases reduced diluted shares from 388 million in 2023 to 378 million in 20257.

Free cash flow pays for the buybacks but not the deals. Free cash flow was $6,337 million in 20258, less than half of the capital deployed. The rest is borrowed, which the page on debt covers.

The buyback programme has little room left. The board authorized up to $5.00 billion of repurchases on 6 November 20259, and after the first half of 2026 $1.00 billion remained10. The quarterly dividend is $0.47 a share11. At the planned pace, a new authorization will be needed before the end of 2026.

This facet works if acquisitions and buybacks together earn more than the cost of the debt used to fund them. Repurchases of $4,000 million in the first half are the pace to compare against the full-year plan.

Moat trajectory: Holding steady

Buybacks $3,000M (2025), $4,000M in H1 2026.

The number that tests this moat
Reported
Share repurchases, first half 2026
$4,000M (H1 2026), against $2,000M (H1 2025)

The pace of returns; buybacks funded by borrowing while acquisitions continue would raise leverage.

Source: Thermo Fisher Form 10-Q, Q2 2026 ↗
⚠ Threats to the moat
⚠ THREAT 01
Buying Back Stock With Proceeds Not Yet Received
Thermo Fisher spent about $1 billion on buybacks from a business sale that had not yet closed.
References
  1. ReportedThermo Fisher describes its priorities plainly: "our capital deployment strategy continues to prioritize strategic M&A complemented by a return of capital to our shareholders".
    Thermo Fisher Scientific second-quarter 2026 earnings call transcript (Motley Fool) - organic growth by segment and market, China, the raised 2026 guidance, leverage, adjusted ROIC and the microbiology sale. Figures from the transcript body, not the summary block - organic growth by segment, end market and region, and the microbiology sale. — Q2 2026 · publ. 23 July 2026 · source ↗
  2. ReportedIn 2025 it deployed approximately $16.5 billion, $13 billion committed to acquisitions and $3.6 billion returned.
    Thermo Fisher Scientific fourth-quarter and full-year 2025 results, Form 8-K exhibit 99.1 - adjusted EPS, free cash flow, capital deployment, the Accelerator offering and the OpenAI collaboration. — FY2025 · publ. 29 January 2026 · source ↗
  3. ReportedThe company bought back $3,000 million of stock in 2025 and paid $636 million of dividends.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - financial statements: income, cash flow, repurchases, debt and equity. — FY2025 · publ. 26 February 2026 · source ↗
  4. ReportedIn the first half of 2026 it bought back $4,000 million, twice the $2,000 million of a year earlier, and it plans about $4 billion for the year.
    Thermo Fisher Scientific Form 10-Q for the quarter ended 27 June 2026 - revenue by business and by type, the Clario purchase price, the microbiology sale, share repurchases, dividends and the balance sheet. — Q2 2026 · publ. 31 July 2026 · source ↗
  5. ReportedIn the first half of 2026 it bought back $4,000 million, twice the $2,000 million of a year earlier, and it plans about $4 billion for the year.
    Thermo Fisher Scientific second-quarter 2026 earnings call transcript (Motley Fool) - organic growth by segment and market, China, the raised 2026 guidance, leverage, adjusted ROIC and the microbiology sale. Figures from the transcript body, not the summary block - 2026 guidance, capital deployment, leverage and adjusted ROIC. — Q2 2026 · publ. 23 July 2026 · source ↗
  6. ReportedThe dividend is small: $1.88 a share, a 0.28% yield.
    Thermo Fisher (TMO) market data - $675.00 at the close on 25 September 2026, market cap $249.58B, dividend $1.88, 52-week range $435.27-$682.98, 29 analysts with a $649.96 target. — September 2026 · publ. 25 September 2026 · source ↗
  7. ReportedRepurchases reduced diluted shares from 388 million in 2023 to 378 million in 2025.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - financial statements: income, cash flow, repurchases, debt and equity. — FY2025 · publ. 26 February 2026 · source ↗
  8. ReportedFree cash flow was $6,337 million in 2025, less than half of the capital deployed.
    Thermo Fisher Scientific fourth-quarter and full-year 2025 results, Form 8-K exhibit 99.1 - adjusted EPS, free cash flow, capital deployment, the Accelerator offering and the OpenAI collaboration. — FY2025 · publ. 29 January 2026 · source ↗
  9. ReportedThe board authorized up to $5.00 billion of repurchases on 6 November 2025, and after the first half of 2026 $1.00 billion remained.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - financial statements: income, cash flow, repurchases, debt and equity. — FY2025 · publ. 26 February 2026 · source ↗
  10. ReportedThe board authorized up to $5.00 billion of repurchases on 6 November 2025, and after the first half of 2026 $1.00 billion remained.
    Thermo Fisher Scientific Form 10-Q for the quarter ended 27 June 2026 - revenue by business and by type, the Clario purchase price, the microbiology sale, share repurchases, dividends and the balance sheet. — Q2 2026 · publ. 31 July 2026 · source ↗
  11. ReportedThe quarterly dividend is $0.47 a share.
    Thermo Fisher Scientific Form 10-Q for the quarter ended 27 June 2026 - revenue by business and by type, the Clario purchase price, the microbiology sale, share repurchases, dividends and the balance sheet. — Q2 2026 · publ. 31 July 2026 · source ↗
Sources
Generated September 28, 2026